Answers are grounded in this paper and cite their sources.
N-Acetyltransferase phenotype has been determined in 109 control subjects and in 23 patients with bladder cancer. Sixty-two per cent of control, and 39% of patients with bladder cancer were phenotypically slow acetylators. This difference was not significant. N-Acetyltransferase phenotype is unlikely to be a major determinant in the development of bladder cancer in the Turkish population.
No takes yet. Share an insight, caveat, or question.
Karakaya et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: